FIELD: chemistry; pharmaceutics.
SUBSTANCE: invention relates to a prodrug of celecoxib of formula I or a pharmaceutically acceptable salt thereof, a method for production thereof, medicinal agent or a pharmaceutical composition based thereon and use thereof for preparing a medicinal agent for preventing and/or treating inflammation of eye tissue. Also disclosed are eye drops for preventing and/or treating inflammation of eye tissue, containing the following components per 100 ml of eye drops: 0.1 g of a compound of formula I according to cl. 1 or 2, 0.05 g of Tween-80, 0.45 g of polyoxyethylene hydrogenated castor oil 40, 0.9 g of sodium chloride, 0.01 g of benzalkonium chloride, the rest is distilled water; wherein the pH value of the eye drops is 5.5–6.5.
EFFECT: use of the group of inventions makes it possible to effectively treat inflammations of eye tissue.
10 cl, 2 dwg, 4 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITION AND METHODS OF ITS PREPARATION AND USE | 2019 |
|
RU2812316C2 |
COMPOSITION OF AN AQUEOUS SUSPENSION COMPRISING NANOPARTICLES OF MACROLIDE ANTIBIOTICS | 2014 |
|
RU2707748C2 |
SALT FORM OF ISOQUINOLINONE TYPE COMPOUND AS ROCK INHIBITOR AND METHOD FOR ITS PREPARATION | 2021 |
|
RU2821792C1 |
PHOSPHOLIPID NANOPARTICLE INDOMETACIN APPLICABLE IN OPHTHALMOLOGY | 2011 |
|
RU2456979C1 |
WATER-BASED LIQUID COMPOSITION CONTAINING AMIDE COMPOUND | 2007 |
|
RU2476219C2 |
PHARMACEUTICAL COMPOSITION FOR TREATING EYE DISEASES RELATED TO EYE TISSUE METABOLIC DISEASE AND INFLAMMATORY EYE TISSUE INJURY | 2013 |
|
RU2521337C1 |
DERIVATIVES OF INDOLE AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | 1999 |
|
RU2212404C2 |
INTRAOCULAR IMPLANTS CONTAINING PROSTAMIDES | 2014 |
|
RU2666603C2 |
PHARMACEUTICAL COMPOSITION FOR GLAUCOMA TREATMENT | 1993 |
|
RU2102069C1 |
SUBSTITUTED 2-HYDROXY-3-[1-(1H-IMIDAZOLE-4-YL)-ALKYL]-BENZENE CARBOXIMIDEAMIDES, THEIR OPTICAL ISOMERS AND THEIR RACEMIC MIXTURES OR THEIR NONTOXIC OPHTHALMOLOGICALLY ACCEPTABLE ACID SALTS | 1994 |
|
RU2125557C1 |
Authors
Dates
2024-07-08—Published
2021-06-08—Filed